Belite Bio, Inc BLTE
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -4.87%
- 1 year
- +35.38%
- Market cap
- 6.13B
- EPS (ttm)
- -2.74
- Shares out
- 40.27M
- Forward P/E
- 67.33
- YTD return
- -4.87%
- 1-year return
- +35.38%
- Volume
- 149.88K
- Avg volume
- 177.40K
- Open
- 154.47
- Previous close
- 153.67
- Day's range
- 152.03 – 157.47
- 52-week range
- 102.00 – 200.00
- Beta
- -1.19
- Analysts
- Strong Buy
- Price target
- 227.44 (+49.5%)
- Earnings date
- Nov 9, 2026
2Y +82.46 (+118.29%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.10%
- Short % of float
- 6.03%
- 50-day average
- 161.32
- 200-day average
- 160.38
Analyst view
Consensus: strong buy
- Target (low)
- 185.00
- Target (mean)
- 227.44
- Target (high)
- 303.00
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.76875.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.78627 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.73 | -0.70 | +0.03 | +4.11% |
| May 20, 2026 | Mar 31, 2026 | -0.60 | -0.34 | +0.26 | +43.33% |
| Mar 2, 2026 | Dec 31, 2025 | -0.56 | -0.38 | +0.18 | +32.14% |
| Nov 10, 2025 | Sep 30, 2025 | -0.53 | -0.65 | -0.12 | -22.64% |
| Aug 11, 2025 | Jun 30, 2025 | -0.47 | -0.50 | -0.03 | -6.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 9, 2026 | Mizuho | main | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 4, 2026 | Canaccord Genuity | init | — | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 14, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- belitebio.com
News
Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19 
Belite Bio Announces Uplisting to the Nasdaq Global Select Market 
Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1 
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences 
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences 
Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC 
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Your note
Sign in to keep a note on BLTE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN WAN-SHAN | Director | Sale | Apr 8, 2026 | 9,096 |
| CHUANG HAO-YUAN | Chief Financial Officer | Sale | Sep 7, 2026 | 26,038 |
| LIN YU-HSIN | Chief Executive Officer | Sale | Sep 7, 2026 | 70,134 |
| MATA NATHAN L. | Officer | Sale | May 6, 2026 | 0 |
| SCHOLL HENDRIK PETER | Officer | Sale | Sep 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 7.64% | 3,077,219 | 468.26M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 3.06% | 1,232,877 | 187.61M | Jun 29, 2026 |
| RTW Investments LP | 1.78% | 715,332 | 108.85M | Jun 29, 2026 |
| Millennium Management Llc | 1.23% | 494,564 | 75.26M | Jun 29, 2026 |
| Maverick Capital Ltd. | 0.98% | 396,311 | 60.31M | Jun 29, 2026 |
| Eventide Asset Management LLC | 0.97% | 390,829 | 59.47M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.97% | 390,829 | 59.47M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.20% | 80,462 | 12.24M | Jun 29, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF | 0.07% | 30,052 | 4.57M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 6,727 | 1.02M | Aug 30, 2026 |
| T. ROWE PRICE Eqy. SERIES, INC.-T. Rowe Price Health Sciences PORT. | 0.01% | 5,400 | 821.72K | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity ZERO International Index Fund | 0.01% | 5,934 | 902.98K | Aug 30, 2026 |